| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/18/2009 | US20090156511 Agent for Enhancing Antiseptic Power |
| 06/18/2009 | US20090156501 Identification of ligands by selective amplification of cells transfected with receptors |
| 06/18/2009 | US20090156493 Urocortin-iii and uses thereof |
| 06/18/2009 | US20090156413 Method, system, apparatus and device for discovering and preparing chemical compounds for medical and other uses |
| 06/18/2009 | US20090155928 Modulating robo: ligand interactions |
| 06/18/2009 | US20090155912 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 06/18/2009 | US20090155393 Method for prolonging the life of animals |
| 06/18/2009 | US20090155382 Methods and Compositions for Heavy Metal Detoxification |
| 06/18/2009 | US20090155372 Method of manufacturing modified release dosage forms |
| 06/18/2009 | US20090155359 Granulated particles, tablets and method for producing granulated particles |
| 06/18/2009 | US20090155326 Layered drug delivery polymer monofilament fibers |
| 06/18/2009 | US20090155281 Methods of using antibodies that bind both bcma and taci |
| 06/18/2009 | US20090155273 Remedies for inflammatory bowel diseases |
| 06/18/2009 | US20090155242 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response |
| 06/18/2009 | US20090155240 Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs |
| 06/18/2009 | US20090155203 Thrombopoietin mimetics |
| 06/18/2009 | US20090155202 modulating the expression of a gene by forming complexes between dsDNA and novel DNA-binding polymers comprising N-terminal thiophene-containing moieties which exhibit selectivity for T-A base pairs |
| 06/18/2009 | US20090155178 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/18/2009 | US20090155174 RNA Interference Mediating Small RNA Molecules |
| 06/18/2009 | US20090155165 Anti-igf-i receptor antibody |
| 06/18/2009 | CA2708146A1 Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| 06/18/2009 | CA2706658A1 Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition |
| 06/17/2009 | EP2071481A2 Method system, apparatus and device for discovering and preparing chemical compounds for medical and other uses |
| 06/17/2009 | EP2071036A2 Methods for identifying RNA-binding compounds |
| 06/17/2009 | EP2070939A1 Modulators of pharmacological agents |
| 06/17/2009 | EP2070927A1 Fused heterocyclic derivative |
| 06/17/2009 | EP2070921A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 06/17/2009 | EP2070920A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
| 06/17/2009 | EP2070919A1 Spiroquinone compound and pharmaceutical composition |
| 06/17/2009 | EP2070908A1 Compound having benzamide skeleton and cyclooxygenase (cox-1)-selective inhibitory activity |
| 06/17/2009 | EP2070549A1 Therapeutic agent for acceleration of spinal nerve repair comprising desacyl ghrelin or derivative thereof as active ingredient |
| 06/17/2009 | EP2070548A1 Diagnosis and treatment of cancer using anti-ereg antibody |
| 06/17/2009 | EP2070546A1 Preventives/remedies for cancer |
| 06/17/2009 | EP2069320A2 Process for the synthesis of ramelteon and its intermediates |
| 06/17/2009 | EP2068931A1 Treatment of fibrosis |
| 06/17/2009 | EP2068871A1 Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression |
| 06/17/2009 | EP2068861A2 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication |
| 06/17/2009 | EP2068849A2 Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| 06/17/2009 | EP1602669B1 Antibody against a tumor-specific antigen as target |
| 06/17/2009 | EP1566384B1 Novel azole derivatives |
| 06/17/2009 | EP1499616B1 Heterocyclic compounds |
| 06/17/2009 | EP1439839B1 A combination comprising combretastatin and anticancer agents |
| 06/17/2009 | EP1435957B1 Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
| 06/17/2009 | EP1435786A4 Pesticidal formulations |
| 06/17/2009 | EP1409544B1 Human dr4 antibodies and uses thereof |
| 06/17/2009 | EP1357115B1 Alkanoic acid derivatives, process for their production and use thereof |
| 06/17/2009 | EP1337518B1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| 06/17/2009 | EP1171428B1 Fab i inhibitors |
| 06/17/2009 | CN100500663C N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
| 06/17/2009 | CN100500662C Alkyl ether derivatives or salts thereof |
| 06/17/2009 | CN100500658C Pharmaceutical composition of male sexual dysfunction |
| 06/17/2009 | CN100500654C Tetrahydrocarbazol derivatives as ligands for g-protein-coupled receptors (gpcr) |
| 06/17/2009 | CN100500211C Methods of therapy with thrombin derived peptides |
| 06/17/2009 | CN100500210C Use of il-18 inhibitors in hypersensitivity disorders |
| 06/16/2009 | US7547730 Preventive and/or therapeutic treatment of hyperlipidemia or non-insulin dependent diabetes mellitus which comprises dministering orally a polyprenyl compound 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (NIK-333); antidiabetic and -lipemic agents |
| 06/16/2009 | US7547719 Thrombopoietin mimetic; useful as an agonist of the TPO receptor, particularly in enhancing platelet production; treatment of thrombocytopenia |
| 06/16/2009 | US7547716 Sulfonamide derivatives |
| 06/16/2009 | US7547711 Heterocyclic inhibitors of kinases |
| 06/16/2009 | US7547702 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents |
| 06/16/2009 | US7547700 Such as (3-chloro-4-fluorophenyl)(4-fluoro-4-{[(5-hydoxypyridin-2-ylmethyl)amino]methyl}piperidin-1-yl)methanone; serotonin receptor agonists; for treating depression, pain, and substance abuse |
| 06/16/2009 | US7547693 Piperidine derivative |
| 06/16/2009 | US7547686 Combretastatin A-3 prodrug |
| 06/16/2009 | US7547680 Benzimidazole derivatives and medical uses thereof |
| 06/16/2009 | US7547543 Retinoid-Related Orphan Receptor (ROR) receptor response element ; drug screening |
| 06/16/2009 | US7547532 Three-dimensional structure of prostaglandin D synthase and utilization thereof |
| 06/16/2009 | US7547513 Mutants of deoxycytidine kinase having extended enzymatic activity |
| 06/16/2009 | US7547439 Elicit immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2; polypeptide |
| 06/16/2009 | CA2451474C Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| 06/16/2009 | CA2388314C Imidazole derivatives as phosphodiesterase vii inhibitors |
| 06/16/2009 | CA2385995C Quinuclidine compound and medicament comprising the compound as active ingredient |
| 06/16/2009 | CA2362082C 2-n-substituted or unsubstituted-2-amino-5-methylpiperidine-3,4-diols and process for the preparation thereof |
| 06/16/2009 | CA2353063C Benzimidazole compounds that are vitronectin receptor antagonists |
| 06/16/2009 | CA2343732C Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto |
| 06/16/2009 | CA2158322C Immunoconjugate comprising an anti-egf receptor antibody and interleukin-8 |
| 06/11/2009 | WO2009073756A1 Combination therapies using melengestrol acetate and zilpaterol or its salts |
| 06/11/2009 | WO2009073683A2 Methods of treating copd |
| 06/11/2009 | WO2009072649A1 4-arylphenyl derivative |
| 06/11/2009 | WO2009072628A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 06/11/2009 | WO2009072581A1 Lactam compound or salt thereof, and ppar activator |
| 06/11/2009 | WO2009072578A1 Bone resorption inhibitor |
| 06/11/2009 | WO2009072576A1 Bone formation stimulator |
| 06/11/2009 | WO2009072267A1 Abcg2 inhibitor |
| 06/11/2009 | WO2009071252A1 Nonsteroidal progesterone receptor modulators |
| 06/11/2009 | WO2008155390A3 Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. |
| 06/11/2009 | WO2002099058A3 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 06/11/2009 | US20090151013 Modified ES cells and ES cell-specific genes |
| 06/11/2009 | US20090149637 Human antibodies derived from immunized xenomice |
| 06/11/2009 | US20090149635 Antibodies to human zcytor17 ligand |
| 06/11/2009 | US20090149548 Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| 06/11/2009 | US20090149541 Method of delaying the onset of clinically definite multiple sclerosis |
| 06/11/2009 | US20090149537 Use of Bile Acid or Bile Salt Fatty Acid Conjugates |
| 06/11/2009 | US20090149509 Peptidyl deformylase inhibitors used for inhibiting bacteria or preventing bacterial contamination of a cell culture medium; 2 (S)-hydroxy-3 (R)-[2 (S)-oxazol-2-yl-pyrrolidine-1-carbonyl)-heptanoic acid hydroxamide |
| 06/11/2009 | US20090149460 New Compounds |
| 06/11/2009 | US20090149445 Tricyclic steroid hormone nuclear receptor modulators |
| 06/11/2009 | US20090149444 Benzylamine analogues |
| 06/11/2009 | US20090149431 Eplerenone Drug Substance Having High Phase Purity |
| 06/11/2009 | US20090149413 RORS as Modifiers of the p21 Pathway and Methods of Use |
| 06/11/2009 | US20090149404 Oligonucleotide analogues and methods utilizing the same |
| 06/11/2009 | US20090148855 Nucleic acid encoding or targeting sodium channel scn3a alpha subunits |
| 06/11/2009 | US20090148531 Rate-controlled particles |